Spanish startup Seqera Labs has raised $5.5 million (€4.7M) in seed funding in a spherical co-led by European enterprise capitalists Talis Capital and Speedinvest.
Present investor BoxOne Ventures additionally participated within the spherical. A grant from the Chan Zuckerberg Initiative, based by Mark Zuckerberg and Dr Priscilla Chan to assist important open-source software program in science, is included within the funding.
WHAT IT DOES
Seqera Labs supplies information orchestration and workflow software program for all times sciences. The spin-out from the Centre for Genomic Regulation was based in 2018 by the creators of open-source workflow and information orchestration software program, Nextflow.
Its core know-how allows scientists to assemble and deploy scalable information evaluation pipelines in multi-cloud environments. The software program deployment mannequin goals to make sure information by no means leaves an organisation’s infrastructure boundary and allows computation to be moved to the information.
In the course of the pandemic, the software program was utilized to world SARS-CoV-2 sequencing efforts. Sequencing centres and specialists collaborated to develop pipelines for the evaluation of COVID-19 samples utilizing Nextflow’s platform which led to the identification and surveillance of variants together with Alpha and Delta.
The platform is chargeable for processing the UK’s COVID information, which makes up round 25% of COVID information globally.
Seqera works with six of the world’s largest pharma firms, and is transferring into the personalised oncology area, working with biotech agency Gritstone bio.
WHAT IT’S FOR
The corporate will use the funding to additional develop its know-how and develop its North American presence.
THE LARGER CONTEXT
Earlier this 12 months, a brand new centre for enhancing native genomic analysis and treating sufferers with genetic problems opened within the United Arab Emirates (UAE).
In the course of the pandemic, UAE-based synthetic intelligence (AI) and cloud computing firm Group 42 introduced it was working with the UK’s Oxford Nanopore Applied sciences, to develop know-how which might quickly and precisely detect SARS-CoV-2.
ON THE RECORD
Evan Floden, CEO and cofounder at Seqera Labs, stated: “The final decade has seen an intensified demand for instruments that may handle and course of advanced information. From personalised immunogenic vaccines to new diagnostics, our clients are performing work paramount to our world well being.”
Paolo Di Tommaso, CTO and cofounder at Seqera Labs, stated: “This backing allows the challenge to deal with new, greater challenges. We’re working to convey all our customers modern options whereas sustaining a powerful hyperlink to the challenge’s core values of openness, agility, scalability and interoperability.”
Kirill Tasilov, principal at Talis Capital, stated: “Nextflow is already a ubiquitous answer on this area and Seqera is driving these capabilities at an enterprise degree – and in doing so, is bringing all the life sciences trade into the fashionable age. We’re thrilled to be part of Seqera’s journey.”
Arnaud Bakker, principal at Speedinvest, stated: “Seqera’s open and cloud-first framework supplies a complicated tooling package permitting organisations to scale advanced deployments of knowledge evaluation and allow data-driven life sciences options.”